Article
Sex differences in gastric cancer mutational burden reflect MLH1-associated epigenetic regulation.
BMC cancer - 15 Jun 2026
Klein Noa, Shweiki Dorit
Abstract excerpt
BACKGROUND: Tumor mutational burden (TMB) is widely used as a biomarker for predicting response to immune checkpoint inhibitors. Therefore, understanding its variability across patient groups, particularly between sexes, and its underlying biological determinants is of critical importance. METHODS: We analyzed autosomal TMB and its association with DNA repair-related regulatory mechanisms in gastric cancer across...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
